Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-93269 (Alnuctamab) in Relapsed and Refractory Multiple Myeloma
NCT03486067Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Apr 2018
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of alnuctamab in multiple myeloma (MM) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Adverse Events (AEs) up to 63 months, Dose Limiting Toxicity up to 60 months and 2 more. Started Apr 2018; status: terminated.
02
Drugs
alnuctamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03486067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486067.